Multicentric castleman's disease: A challenging diagnosis

Pathology and Oncology Research

Volumn 19, Issue 3, 2013, Pages 345-351

  Műzes, Györgyi ^a   Sipos, Ferenc ^a   Csomor, Judit ^a   Sréter, Lídia ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Differential diagnosis; HHV 8; IL 6; Monoclonal antibodies; Multicentric Castleman's disease; Therapy

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; AZATHIOPRINE; BLEOMYCIN; BORTEZOMIB; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; DOXORUBICIN; ETOPOSIDE; GANCICLOVIR; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6; PREDNISONE; RITUXIMAB; THALIDOMIDE; TOCILIZUMAB; VALGANCICLOVIR; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; ZIDOVUDINE;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; CYTOKINE RELEASE; DIFFERENTIAL DIAGNOSIS; DRUG MEGADOSE; HERPES VIRUS INFECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LYMPHADENOPATHY; MALIGNANT TRANSFORMATION; MULTICENTRIC CASTLEMAN DISEASE; MULTIPLE MYELOMA; PATHOGENESIS; PLASMA CELL DYSCRASIA; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; VIRUS LOAD; CLASSIFICATION; GIANT LYMPH NODE HYPERPLASIA;

GIANT LYMPH NODE HYPERPLASIA; HUMANS;

EID: 84880329992     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-013-9619-z     Document Type: Review

References (80)

1. Castleman B, Towne VW (1954) Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. Cabot. N Engl J Med 251:396-400
2. Herrada J, Cabanillas F, Rice L, Manning J, Pugh W (1998) The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 128:657-662
3. Roca B (2009) Castleman's disease. A review. AIDS Rev 11:3-7.
4. Keller AR, Hochholzer L, Castleman B (1972) Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29:670-683
5. Gaba AR, Stein RS, Sweet DL, Variakojis D (1978) Multicentric giant lymph node hyperplasia. Am J Clin Pathol 69:86-90
6. Peterson BA, Frizzera G (1993) Multicentric Castleman's disease. Semin Oncol 20:636-647
7. Maslovsky I, Uriev L, Lugassy G (2000) The heterogeneity of Castleman disease: report of five cases and review of the literature. Am J Med Sci 320:292-295
8. Waterston A, Bower M (2004) Fifty years of multicentric Castleman's disease. Acta Oncol 43:698-704
9. Frizzera G, Peterson BA, Bayrd ED, Goldman A (1985) A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 3:1202-1216
10. Frizzera G (2001) Atypical lymphoproliferative disorders. In: Knowles DM (ed) Neoplastic hematopathology. Lippincott, Williams and Wilkins, Philadelphia, pp 595-621
11. Collins LS, Fowler A, Tong CY, de Ruiter A (2006) Multicentric Castleman's disease in HIV infection. Int J STD AIDS 17:19-24
12. Soulier J, Grollet L, Oksenhendler E, et al. (1995) Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86:1276-1280
13. Cronin DM, Warnke RA (2009) Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol 16:236-246
14. Shahidi H, Myers JL, Kvale PA (1995) Castleman's disease. Mayo Clin Proc 70:969-977
15. Seida A, Wada J, Morita Y, et al. (2004) Multicentric Castleman's disease associated with glomerular microangiopathy and MPGN-like lesion: does vascular endothelial cell-derived growth factor play causative or protective roles in renal injury? Am J Kidney Dis 43:E3-E9
16. Suneja S, Chidambaram M, Herzenberg AM, Bargman JM (2009) Kidney involvement in multicentric castleman disease. Am J Kidney Dis 53:550-554
17. Guihot A, Couderc LJ, Agbalika F, et al. (2005) Pulmonary manifestations of multicentric Castleman's disease in HIV infection: a clinical, biological and radiological study. Eur Respir J 26:118-125
18. Weisenburger DD, Nathwani BN, Winberg CD, Rappaport H (1985) Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. Hum Pathol 16:162-172
19. Gessain A, Sudaka A, Brière J, et al. (1996) Kaposi sarcoma-associated herpes-like virus (human herpesvirus type 8) DNA sequences in multicentric Castleman's disease: is there any relevant association in non-human immunodeficiency virus-infected patients? Blood 87:414-416
20. Izuchukwu IS, Tourbaf K, Mahoney MC (2003) An unusual presentation of Castleman's disease: a case report. BMC Infect Dis 3:20
21. Oksenhendler E, Duarte M, Soulier J, et al. (1996) Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS 10:61-67
22. Oksenhendler E, Boulanger E, Galicier L, et al. (2002) High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 99:2331-2336
23. Larroche C, Cacoub P, Soulier J, et al. (2002) Castleman's disease and lymphoma: report of eight cases in HIV-negative patients and literature review. Am J Hematol 69:119-126
24. Du MQ, Liu H, Diss TC, et al. (2001) Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 97:2130-2136
25. Dupin N, Diss TL, Kellam P, et al. (2000) HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 95:1406-1412
26. Kojima M, Nakamura S, Nishikawa M, Itoh H, Miyawaki S, Masawa N (2005) Idiopathic multicentric Castleman's disease. A clinicopathologic and immunohistochemical study of five cases. Pathol Res Pract 201:325-332
27. Kojima M, Nakamura S, Itoh H, et al. (1997) Systemic lupus erythematosus (SLE) lymphadenopathy presenting with histopathologic features of Castleman' disease: a clinicopathologic study of five cases. Pathol Res Pract 193:565-571
28. Ioachim HL, Cronin W, Roy M, Maya M (1990) Persistent lymphadenopathies in people at high risk for HIV infection. Clinicopathologic correlations and long-term follow-up in 79 cases. Am J Clin Pathol 93:208-218
29. Kojima M, Nakamura S, Shimizu K, et al. (2004) Clinical implication of idiopathic plasmacytic lymphadenopathy with polyclonal hypergammaglobulinemia: a report of 16 cases. Int J Surg Pathol 12:25-30
30. Frizzera G, Banks PM, Massarelli G, Rosai J (1983) A systemic lymphoproliferative disorder with morphologic features of Castleman's disease. Pathological findings in 15 patients. Am J Surg Pathol 7:211-231
31. Koo CH, Nathwani BN, Winberg CD, Hill LR, Rappaport H (1984) Atypical lymphoplasmacytic and immunoblastic proliferation in lymph nodes of patients with autoimmune disease (autoimmune-disease-associated lymphadenopathy). Med (Baltimore) 63:274-290
32. Bianchi MM, Narváez J, Santo P, et al. (2009) Multicentric Castleman's disease mimicking adult-onset Still's disease. Joint Bone Spine 76:304-307
33. Bonekamp D, Horton KM, Hruban RH, Fishman EK (2011) Castleman disease: the great mimic. Radiographics 31:1793-1807
34. Polizzotto MN, Uldrick TS, Hu D, Yarchoan R (2012) Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV-MCD) and the KSHV inflammatory cytokine syndrome. Front Microbiol 3:73
35. Nishimoto N, Kishimoto T (2006) Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2:619-626
36. Kishimoto T (2006) Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 8:S2
37. Kishimoto T (1989) The biology of interleukin-6. Blood 74:1-10
38. Vinzio S, Ciarloni L, Schlienger JL, Rohr S, Méchine A, Goichot B (2008) Isolated microcytic anemia disclosing a unicentric Castleman disease: the interleukin-6/hepcidin pathway? Eur J Intern Med 19:367-369
39. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T (2003) Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101:2461-2463
40. Sullivan RJ, Pantanowitz L, Casper C, Stebbing J, Dezube BJ (2008) HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Clin Infect Dis 47:1209-1215
41. Moore PS, Chang Y (1995) Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N Engl J Med 332:1181-1185
42. Davis DA, Humphrey RW, Newcomb FM, et al. (1997) Detection of serum antibodies to a Kaposi's sarcoma-associated herpesvirus-specific peptide. J Infect Dis 175:1071-1079
43. Kedes DH, Ganem D, Ameli N, Bacchetti P, Greenblatt R (1997) The prevalence of serum antibody to human herpesvirus 8 (Kaposi sarcoma-associated herpesvirus) among HIV-seropositive and high-risk HIV-seronegative women. JAMA 277:478-481
44. Pauk J, Huang ML, Brodie SJ, et al. (2000) Mucosal shedding of human herpesvirus 8 in men. N Engl J Med 343:1369-1377
45. Regamey N, Tamm M, Wernli M, et al. (1998) Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients. N Engl J Med 339:1358-1363
46. Levi JE, Nascimento MC, Sumita LM, et al. (2011) Non-detection of human herpesvirus 8 (HHV-8) DNA in HHV-8-seropositive blood donors from three Brazilian regions. PLoS One 6:e23546
47. Damania B (2007) DNA tumor viruses and human cancer. Trends Microbiol 15:38-44
48. Fukumoto H, Kanno T, Hasegawa H, Katano H (2011) Pathology of Kaposi's Sarcoma-Associated Herpesvirus infection. Front Microbiol 2:175
49. Bélec L, Mohamed AS, Authier FJ, et al. (1999) Human herpesvirus 8 infection in patients with POEMS syndrome-associated multicentric Castleman's disease. Blood 93:3643-3653
50. Yamasaki S, Iino T, Nakamura M, et al. (2003) Detection of human herpesvirus-8 in peripheral blood mononuclear cells from adult Japanese patients with multicentric Castleman's disease. Br J Haematol 120:471-477
51. Darazam IA, Mansouri SD, Karimi S, et al. (2010) A 25-year-old woman with cough, constitutional symptoms and lymphadenopathy. Tanaffos 9:80-83
52. Schulte KM, Talat N (2010) Castleman's disease-a two compartment model of HHV8 infection. Nat Rev Clin Oncol 7:533-543
53. Martró E, Cannon MJ, Dollard SC, et al. (2004) Evidence for both lytic replication and tightly regulated human herpesvirus 8 latency in circulating mononuclear cells, with virus loads frequently below common thresholds of detection. J Virol 78:11707-11714
54. Neipel F, Albrecht JC, Ensser A, et al. (1997) Human herpesvirus 8 encodes a homolog of interleukin-6. J Virol 71:839-842
55. Cesarman E (2011) Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients. Cancer Lett 305:163-174
56. El-Daly H, Bower M, Naresh KN (2010) Follicular dendritic cells in multicentric Castleman disease present human herpes virus type 8 (HHV8)-latent nuclear antigen 1 (LANA1) in a proportion of cases and is associated with an enhanced T-cell response. Eur J Haematol 84:133-136
57. El-Osta HE, Kurzrock R (2011) Castleman's disease: from basic mechanisms to molecular therapeutics. Oncologist 16:497-511
58. Casper C (2005) The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol 129:3-17
59. Dispenzieri A, Gertz MA (2005) Treatment of Castleman's disease. Curr Treat Options Oncol 6:255-266
60. Gill PS, Loureiro C, Bernstein-Singer M, Rarick MU, Sattler F, Levine AM (1989) Clinical effect of glucocorticoids on Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 110:937-940
61. Lajoie G, Kumar S, Min KW, Silva FG (1995) Renal thrombotic microangiopathy associated with multicentric Castleman's disease. Report of two cases. Am J Surg Pathol 19:1021-1028
62. Mylona EE, Baraboutis IG, Lekakis LJ, Georgiou O, Papastamopoulos V, Skoutelis A (2008) Multicentric Castleman's disease in HIV infection: a systematic review of the literature. AIDS Rev 10:25-35
63. Seo HY, Kim EB, Kim JW, Shin BK, Kim SJ, Kim BS (2009) Complete remission in a patient with human herpes virus-8 negative multicentric Castleman disease using CHOP chemotherapy. Cancer Res Treat 41:104-107
64. Bower M, Fox P, Fife K, Gill J, Nelson M, Gazzard B (1999) Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS 13:2105-2111
65. Zietz C, Bogner JR, Goebel FD, Löhrs U (1999) An unusual cluster of cases of Castleman's disease during highly active antiretroviral therapy for AIDS. N Engl J Med 340:1923-1924
66. Berezne A, Agbalika F, Oksenhendler E (2004) Failure of cidofovir in HIV-associated multicentric Castleman disease. Blood 103:4368-4369
67. Casper C, Nichols WG, Huang ML, Corey L, Wald A (2004) Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 103:1632-1634
68. Bower M, Powles T, Williams S, et al. (2007) Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med 147:836-839
69. Gérard L, Bérezné A, Galicier L, et al. (2007) Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol 25:3350-3356
70. Law AB, Ryan G, Lade S, Prince HM (2010) Development of Kaposi's sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient. Int J Hematol 91:347-348
71. Nishimoto N, Sasai M, Shima Y, et al. (2000) Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95:56-61
72. Nishimoto N, Kanakura Y, Aozasa K, et al. (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106:2627-2632
73. Matsuyama M, Suzuki T, Tsuboi H, et al. (2007) Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease. Intern Med 46:771-774
74. Higuchi T, Nakanishi T, Takada K, et al. (2010) A case of multicentric Castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, tocilizumab. J Korean Med Sci 25:1364-1367
75. Muzes G, Sipos F, Csomor J, Sréter L (2012) Successful tocilizumab treatment in a patient with HHV8-positive and HIV-negative multicentric Castleman's disease of plasma cell type nonresponsive to R-CVP therapy. doi: 10.1111/apm.12029
76. van Rhee F, Fayad L, Voorhees P, et al. (2010) Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol 28:3701-3708
77. Starkey CR, Joste NE, Lee FC (2006) Near-total resolution of multicentric Castleman disease by prolonged treatment with thalidomide. Am J Hematol 81:303-304
78. Hess G, Wagner V, Kreft A, Heussel CP, Huber C (2006) Effects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman disease. Br J Haematol 134:544-545
79. Sobas MA, Alonso Vence N, Diaz Arias J, Bendaña Lopez A, Fraga Rodriguez M, Bello Lopez JL (2010) Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant). Ann Hematol 89:217-219
80. Galeotti C, Tran TA, Franchi-Abella S, Fabre M, Pariente D, Koné-Paut I (2008) IL-1RA agonist (anakinra) in the treatment of multifocal castleman disease: case report. J Pediatr Hematol Oncol 30:920-924